Overall, our results indicate that CAVD in CHIP carriers occurs through the typical valvular alterations of the disease but also highlight an augmented involvement of adaptive immune activation and frequently an involvement of humoral responses. This evidence concerns the gene STUB1 and congenital bilateral aplasia of vas deferens from CFTR mutation.